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Conjugate Vaccines:  Manufacturing and quality control
Topics to be discussed:
• Characteristics of a conjugate vaccine
• Considerations  in production of a conjugate
-- Polysaccharide activation
-- Conjugation
• Quality control and lot release
• Improving conjugation efficiency (yields)
Properties of a good polysaccharide-protein 
conjugate vaccine
• Has defined chemical composition and structure
• Can be manufactured with consistent physical and 
chemical characteristics
• Is safe  - has no inherent toxicity
• Induces high avidity bactericidal or opsonic antibodies
• Induces boostable IgG antibody in infants
• Primes for response upon natural exposure  to the 
polysaccharide
Some currently licensed bacterial polysaccharide
protein conjugate vaccines
Organism        Vaccine              First          Saccharide   Protein       Vaccine
manufacturer    Licensed                             carrier          dose (μg)
Haemophilus
influenzae b
Wyeth
Merck
Sanofi
GSK
1988
1989
1993
1996
Hib oligo
Hib Sz red
Hib PS
Hib PS
CRM197
OMPC
Tet Tox
Tet Tox
10
7.5
10
10
Meningococcal Wyeth
Baxter
Novartis
Sanofi
1999
2000
2000
2005
C Sz red
C De OAc
C oligo
A,C,Y,W 
Sz red
CRM197
Tet Tox
CRM197
Diph Tox
10
10
10
4 each
Pneumococcal      Wyeth            2000             4, 6B, 9V,        CRM197 2
14, 18C, 19F                   (4μg 6B)
23F
Meningo/Hib          GSK                 2005             Hib, MenC      Tet Tox       5 each

Major physical and chemical variables
in production of glycoconjugate vaccines
1. Size of the polysaccharide or oligosaccharide
2. Chemistry for activation of the polysaccharide
3. Choice of carrier protein
4. Saccharide - protein conjugation chemistry
5. Saccharide loading onto protein carrier, ie,
Saccharide to protein ratio
General process for manufacture of a 
conjugate vaccine 
Polysaccharide 
Fermentation
Carrier protein (toxoid) 
Fermentation
Purification
Purification 
(detoxification)
Polysaccharide 
activation
Conjugation then 
purification
Conjugate vaccine
Making a conjugate
For a polysaccharide to be chemically linked
to a protein, the polysaccharide must be
activated, that is, chemically modified.
Methods include:
• Reductive amination
• Cyanylation
• Carbodiimide
Activation Chemistry
Important difference between methods used to
activate the polysaccharide for conjugation
Periodate activation for reductive amination:
Activates by cutting carbon-carbon bonds between 
adjacent carbons having -OH groups to create active
aldehyde groups
Cyanylation
Activtes by randomly changing –OH groups
to active –CN groups
Carbodiimide
Activates at carboxyl groups by replacing –OH with
carbodiimide
Periodate oxidation of polysaccharides

Important lot release tests for
polysaccharide-protein conjugate vaccines
• Purity of polysaccharide and carrier protein 
• Saccharide of known molecular size distribution
• Degree of saccharide activation
• Molecular size of conjugate (a stability measure)
• Vaccine Potency:
¾ Polysaccharide to protein ratio in conjugate
¾ Percent non-conjugated (free) saccharide 
present in monovalent conjugate bulks
Newer physical methods to analyze 
polysaccharide component of a conjugate
 Identity NMR
 Structure NMR
 Purity NMR
 Quantitation              NMR
 Stability SEC-HPLC, NMR
 Size SEC-HPLC, MALLS
600-MHz proton spectrum of pneumococcal
type 17F polysaccharide
Anomeric region Ring region Acetyls Methyls
Stability indicating quality control tests for monovalent 
bulks and final vaccine
• Change in the molecular size of conjugate during storage
• Increase in free (unbound) saccharide over time
• Change in conjugate solubility during storage
• Change in pH during storage
• Change in degree of adsorption, if vaccine adjuvant 
adsorbed
Conjugation efficiency (yields)
• It is very difficult to discern manufacturing yields
• Some manufacturers report high yields based upon
recovery of the carrier protein (not relevant)
• Some do not account for losses during activation
• Yields can be much higher when both the polysaccharide
and protein are activated before conjugation
Yields:
¾ Utilize native amino groups – about 10 to 30%
¾ Utilize activated protein       -- about 50 %
New Aldehyde Conjugation Chemistry using 
activated proteins to improve yields
1.  Hydrazone formation
Aldehyde/hydrazide/reduction 
Benzaldehyde/hydrazide
Activates through the carboxyl groups, not amino
Hydrazones are the condensation of hydrazide or hydrazine 
with aldehyde
2.  Oxime formation
Creates a highly reactive aminooxy group
Schematics for Preparation of Polysaccharide-
Tetanus Toxoid Conjugate using
Hydrazide Chemistry
Tetanus toxoid + Hydrazine  → TT-HEDC
Polysaccharide + NaIO4 → Activated PS
→ Conjugate
Conjugates made with hydrazide activated tetanus toxoid
(TT-H) versus unmodified tetanus toxoid (TT)
TT
TT-H
Conj
Conj
SE-HPLC
Conclusions
9 There are several methodologies for manufacture of 
saccharide-protein conjugate vaccines
9 The polysaccharide or oligosaccharide must be chemically
activated for conjugation to occur
9 It is important to carefully consider the chemistry used for
saccharide acvtivation
9 Activation of both the protein and the polysaccharide will
improve conjugation yields
9 Quality control and lot release testing are described in 
WHO Technical Report series publications for Hib, 
meningococcal and pneumococcal conjugate vaccines
